Corvus Pharmaceuticals (CRVS) Change in Account Payables (2015 - 2026)

Corvus Pharmaceuticals' Change in Account Payables history runs 12 years deep, the most recent figure standing at $2.2 million for Q1 2026.

• In Q1 2026, Change in Account Payables rose 273.16% year-over-year to $2.2 million; the TTM figure through Mar 2026 stood at $3.4 million (up 1225.91% YoY), while the FY2025 annual figure was -$91000.0, down 108.61% from the prior year.
• Change in Account Payables was $2.2 million for Q1 2026 at Corvus Pharmaceuticals, up from $517000.0 in the prior quarter.
• In the past five years, Change in Account Payables ranged from a high of $2.2 million in Q1 2026 to a low of -$2.3 million in Q4 2022.
• Historically, Change in Account Payables has averaged $184235.3 across 5 years, with a median of $210000.0 in 2022.
• Biggest YoY gain for Change in Account Payables was 561.87% in 2025; the steepest drop was 1616.67% in 2025.
• A 5-year view of Change in Account Payables shows it stood at -$2.3 million in 2022, then soared by 105.38% to $121000.0 in 2023, then surged by 485.95% to $709000.0 in 2024, then declined by 27.08% to $517000.0 in 2025, then soared by 326.69% to $2.2 million in 2026.
• The last three Change in Account Payables figures came in at $2.2 million (Q1 2026), $517000.0 (Q4 2025), and -$1.2 million (Q3 2025), per Business Quant data.